メディカルアフェアーズの評判（米国）- 多発性硬化症

米国の神経科医100人を対象としたこの最新の調査によると、いくつかの有名ブランドの多発性硬化症治療薬のメディカルアフェアーズチームの業績は、いまだ複数の重要な分野で途上にあります。

当レポートでは、米国のメディカルアフェアーズについて調査分析し、多発性硬化症を治療する医師の高い期待に、メディカルアフェアーズがどのように応えていけるかを明らかにしています。また、各社の主な多発性硬化症治療薬に対するメディカルアフェアーズチームの現在の業績を比較しています。

回答された主な質問

• 1. 医師はメディカルアフェアーズチームとどの程度の頻度で交流しているのか、またその頻度は増加しているのか、減少しているのか。
• 2. 医師は現在、メディカルアフェアーズチームが提供するサービスをどのような形で利用しているか。
• 3. メディカルアフェアーズのサポートのどのような点が医師にとってもっとも重要で、提供されたサポートにどの程度満足しているか。
• 4. 医師とメディカルアフェアーズチームとの間で、どのようなやりとりをするのが好ましいか、またその頻度はどの程度が好ましいか。
• 5. メディカルアフェアーズチームは医師のニーズにどの程度応えられているか。
• 6. メディカルアフェアーズチームは、特定のブランドで目標を下回っているか、上回っているか。
• 7. 今後、メディカルアフェアーズサービスをどのように改善すれば、より医師のニーズに応えられるか。
• 8. 競合企業のメディカルアフェアーズチームはどの分野でもっとも弱く、もっとも強いか。

According to this latest survey of 100 US neurologists, the performance of multiple sclerosis medical affairs teams for some high profile brands still has a way to go in some key areas. Find out what physicians think is done well; what they want to see more of; and why some are dissatisfied. This report reveals how medical affairs can better meet the high expectations of physicians treating multiple sclerosis. It compares the current performance of medical affairs teams for leading treatments for multiple sclerosis from various companies.

Key Questions Answered:

• 1. How frequently do physicians interact with Medical Affairs teams, and is the frequency of this interaction increasing or decreasing?
• 2. In what ways do physicians currently use the services provided by Medical Affairs teams
• 3. What aspects of Medical Affairs support are most important to physicians and how satisfied are they with the support provided?
• 4. What are the preferred mediums for interactions between physicians and Medical Affairs teams and what is the preferred frequency of these interactions?
• 5. How successful are Medical Affairs teams at meeting physician needs?
• 6. Are Medical Affairs teams falling short or exceeding goals with any particular brands?
• 7. How can Medical Affairs services be improved to better meet the needs of physicians in the future?
• 8. In what areas are your competitors' Medical Affairs teams weakest and strongest?

Methodology:

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.